FKC288 cell therapy for AL amyloidosis
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new cell therapy called FKC288 for people with AL amyloidosis that hasn't been helped by standard treatments. The goal is to see if it can safely control the disease and improve organ function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 69 years old
- You have been diagnosed with light chain (AL) amyloidosis that has come back or hasn't responded to standard treatments
- Your amyloidosis affects your heart, kidney, or liver
- You have a certain level of abnormal light chains in your blood (dFLC greater than 50 mg/L)
- Your blood counts, kidney, and liver function meet minimum safety levels
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of immunotherapy called CAR T cells that target a protein called BCMA on abnormal cells. It is for people whose light chain amyloidosis has come back or not responded to previous treatments.
This trial tests a CAR T cell therapy that targets two proteins (CD19 and BCMA) on the surface of abnormal plasma cells. It is for people with AL amyloidosis whose disease has come back or did not respond to at least one prior treatment.
This study tests a new treatment called FKC289 for people with AL amyloidosis that has come back or hasn't improved with standard treatments. The goal is to see if it is safe and helps patients.
This study tests a new drug that targets two proteins on the cells causing amyloidosis, aiming to reduce the harmful protein buildup in the body. It is for people who have just been diagnosed with this condition and have not yet had other treatments for it.
This early-stage trial tests a new cell therapy using your own immune cells (genetically modified to target amyloid-producing cells) to treat light chain amyloidosis that hasn't responded to standard treatments. The goal is to help patients whose disease has come back or stopped responding to previous therapies.
This trial tests a new CAR-T cell therapy (GC012F) that targets two proteins, CD19 and BCMA, on abnormal plasma cells. It's for people with AL amyloidosis who have already tried at least one treatment.
Hear when a new Light Chain Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.